BioXcel Therapeutics, Inc. (BTAIQ) Total liabilities 2022–2025
BioXcel Therapeutics, Inc. (BTAIQ) total liabilities at each fiscal year-end, per SEC filings.
$140.4MFY2025 · since FY2022: $129.1M → $140.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $140.4M | +6.8% |
| FY2024 | $131.4M | +0.9% |
| FY2023 | $130.2M | +0.9% |
| FY2022 | $129.1M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More BTAIQ financial trends
BTAIQ RevenueBTAIQ Net incomeBTAIQ Net marginBTAIQ Gross profitBTAIQ Gross marginBTAIQ Operating incomeBTAIQ Operating marginBTAIQ Operating cash flowBTAIQ Free cash flowBTAIQ Capital expendituresBTAIQ Return on equityBTAIQ Stock buybacksBTAIQ Dividends paidBTAIQ Total assetsBTAIQ Shareholders’ equityBTAIQ overview →